Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Optimizing Therapy for Relapsed/Refractory Multiple Myeloma: Expert Answers to Your Questions

In this podcast episode, listen to myeloma experts Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, provide their thoughts on optimal treatment for relapsed/refractory multiple myeloma.
Suzanne Lentzsch, MD, PhD
Saad Z. Usmani, MD, MBA, FACP
Released: June 17, 2021

In this podcast episode, Suzanne Lentzsch, MD, PhD, and  Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:

  • Selecting optimal triplet regimen after first relapse
  • Sequencing treatment options after multiple relapses
  • Managing patient expectations when selecting treatments
  • Emerging treatment options for R/R MM


Suzanne Lentzsch, MD, PhD
Director, Multiple Myeloma and Amyloidosis Program
Professor of Medicine
Division of Hematology/Oncology
Columbia University Medical Center
New York, New York

Saad Z. Usmani, MD, MBA, FACP
Clinical Professor of Medicine
Department of Hematologic Oncology & Blood Disorders
Division Chief
Plasma Cell Disorders Division
Levine Cancer Institute/Atrium Health
Charlotte, North Carolina


Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; and Thomas G. Martin, MD discuss the use of BCMA-targeted agents in relapsed/refractory multiple myeloma in an on-demand webcast, from Clinical Care Options (CCO)

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022

Patient-friendly resource on myelodysplastic syndromes from Clinical Care Options (CCO)

person default Sara Tinsley, PhD, ARNP, AOCN Released: October 15, 2021

Download this short summary slideset on myelodysplastic syndromes to help diagnose and manage your patients, from Clinical Care Options (CCO).

Amy E. DeZern, MD, MHS Daniel Pollyea, MD, MS Amer Zeidan, MBBS Released: October 12, 2021

Expert commentary on the pharmacist’s role in caring for CAR T-cell therapy recipients, from Clinical Care Options (CCO)

Zahra Mahmoudjafari, PharmD, BCOP, DPLA Released: October 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.